{"prompt": "['Alliance A221701', '2.4.2. To correlate everolimus exposure (CO) with toxicity.', '3.0', 'PATIENT SELECTION', 'For questions regarding eligibility criteria, see the Study Resources page. Please note that the Study', 'Chair cannot grant waivers to eligibility requirements.', '3.1', 'On-Study Guidelines', 'This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled.', 'All relevant medical and other considerations should be taken into account when deciding', 'whether this protocol is appropriate for a particular patient. Physicians should consider the risks', 'and benefits of any therapy, and therefore only enroll patients for whom this treatment is', 'appropriate.', 'Physicians should consider whether any of the following may render the patient inappropriate', 'for this protocol:', 'Psychiatric illness which would prevent the patient from giving informed consent.', 'Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes', 'mellitus or cardiac disease which, in the opinion of the treating physician, would make', 'this protocol unreasonably hazardous for the patient.', 'Patients with a \"currently active\" second malignancy other than non-melanoma skin', 'cancers or cervical carcinoma in situ. Patients are not considered to have a \"currently', 'active\" malignancy if they have completed therapy and are free of disease for > 3 years.', '3.2', 'Eligibility Criteria', \"Use the spaces provided to confirm a patient's eligibility by indicating Yes or No as appropriate.\", 'It is not required to complete or submit the following page(s).', 'When calculating days of tests and measurements, the day a test or measurement is done is', 'considered Day 0. Therefore, if a test were done on a Monday, the Monday one week later would', 'be considered Day 7.', '3.2.1 Documentation of Disease:', 'Current cancer diagnosis, about to receive oral everolimus 10 mg/day with or without', 'an endocrine agent. Patients about to receive everolimus for off label use for any cancer', 'are also eligible.', '3.2.2', 'Prior Treatment', 'Not currently receiving chemotherapy or any other agent known to cause mucositis', 'or stomatitis. Trastuzumab and ovarian function suppression are allowed.', 'Any prior chemotherapy or other stomatitis/mucositis-causing therapy must be', 'completed at least 2 weeks prior to registration.', '3.2.3 Not currently suffering from stomatitis/mucositis or mouth ulcers. Patients', 'should not have had any stomatitis or mouth pain for at least 7 days prior to registration.', '3.2.4', 'Patients should not receive any other agent which would be considered', 'treatment for stomatitis or impact the primary endpoint.', '3.2.5 No history of candida infection (thrush) within the last 3 months', '3.2.6', 'Not currently being treated with corticosteroids', '14', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '3.2.7 Comorbid conditions', 'No uncontrolled diabetes mellitus, defined by hemoglobin A1C greater than 8%,', 'although A1C is not needed for all patients, HgbA1C< is required for everyone', 'with diabetes or suspected diabetes.', '3.2.8 Patients must be able to read and comprehend English. Local translation,', 'including verbal translation of PROs is not permitted.', '3.2.9 Not pregnant and not nursing, because this study involves an investigational', 'agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and', 'newborn are unknown.', 'Therefore, for women of childbearing potential only, a negative pregnancy test done < 7', 'days prior to registration is required.', '3.2.10 ECOG Performance Status 0, 1 or 2.', '3.2.11 Age > 18 years', '3.2.12 Required Initial Laboratory Values: None', '15', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}